Bookmarks
Leveraging diverse genetic data to improve drug discovery and treatment strategies.
Safe People
Organisation name
Johnson and Johnson
Organisation sector
Commercial
Applicant name(s)
Shuwei Li
Funders/ Sponsors
Safe Projects
Project ID
OFHS240244
Lay summary
Human genetic evidence can greatly improve drug development success. In this study, we will analyze genetic and biological data from diverse groups in the OFH cohort and other populations. Our goal is to confirm drug targets, identify disease biomarkers, and improve treatment strategies. The focus on diversity in OFH helps ensure that treatment benefits a wider range of people. Human genetic evidence can greatly improve drug development success. In this study, we will analyze genetic and biological data from diverse groups in the OFH cohort and other populations. Our goal is to confirm drug targets, identify disease biomarkers, and improve treatment strategies. The focus on diversity in OFH helps ensure that treatment benefits a wider range of people.
Public benefit statement
This research will help people by improving early disease detection and treatment, leading to better and fairer healthcare. By using strong data-driven methods to find and assess drug targets, it supports the development of better treatment, helping people live longer and healthier lives.
Request category type
Public Health Research
Other approval committees
Project start date
22/08/2025
Latest approval date
15/07/2025
Safe Data
Dataset(s) name
Safe Setting
Access type
TRE